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EGFR Mutations Detected in Plasma Are Associated with
Patient Outcomes in Erlotinib Plus Docetaxel-Treated
Non-small Cell Lung Cancer
Philip C. Mack, PhD, William S. Holland, MS, Rebekah A. Burich, MS, Randeep Sangha, MD,
Leslie J. Solis, MS, Yueju Li, MA, Laurel A. Beckett, PhD, Primo N. Lara, Jr., MD,
Angela M. Davies, MD, and David R. Gandara, MD
Purpose: Activating mutations in the epidermal growth factor
receptor (EGFR) are associated with enhanced response to EGFR
tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC),
whereas KRAS mutations translate into poor patient outcomes. We
hypothesized that analysis of plasma for EGFR and KRAS muta-
tions from shed tumor DNA would have clinical utility.
Methods: An allele-specific polymerase chain reaction assay using
Scorpion-amplification refractory mutation system (DxS, Ltd) was
used to detect mutations in plasma DNA from patients with ad-
vanced stage NSCLC treated as second- or third-line therapy on a
phase I/II trial of docetaxel plus intercalated erlotinib.
Results: EGFR mutations were detected in 10 of 49 patients (20%).
Six (12%) had single activating mutations in EGFR, associated with
improved progression-free survival (median, 18.3 months), compared
with all other patients (median, 3.9 months; p  0.008), or those with
wild-type EGFR (median, 4.0 months; p  0.012). Four of 49 patients
harbored a de novo T790M resistance mutation (median progression-
free survival, 3.9 months). EGFR mutational status was associated with
clinical response (45 assessable, p  0.0001); in the six patients with
activating mutations, all achieved complete (33%) or partial (67%)
response. All CR patients had E19del detectable in both tumor and
plasma. KRAS mutations were detected in two of 49 (4%) patients,
both of whom had rapid progressive disease.
Conclusions: Activating EGFR mutations detected in shed DNA in
plasma are significantly associated with favorable outcomes in
patients with advanced NSCLC receiving docetaxel plus intercalated
erlotinib. The addition of docetaxel in this schedule did not diminish
the efficacy of erlotinib against patients with EGFR activating
mutations.
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Lung cancer is the leading cause of cancer-related death inthe United States.1 A current target for therapeutics is the
epidermal growth factor receptor (EGFR). Commonly expressed
in non-small cell lung cancer (NSCLC), EGFR abnormalities
may lead to constitutive signaling through downstream tyrosine
kinase pathways involved in cell proliferation and survival.
Small molecule inhibitors of EGFR such as gefitinib and
erlotinib have been introduced into the clinic. Large random-
ized phase III trials testing these agents in unselected patients
have demonstrated mixed results.2–8
Experience with EGFR tyrosine kinase inhibitor (TKI)
therapy has led to the recognition of clinical characteristics
associated with higher likelihood of response, notably Asian
patients, females, never-smokers, and adenocarcinoma histol-
ogy.8–11 However, the presence of certain activating EGFR
mutations seems to be a better predictor of response. Tumor
molecular analyses including EGFR protein expression, gene
copy number, tyrosine kinase domain mutations, and poly-
morphisms have also been reported as potential predictive
biomarkers.2,12–18 Additional studies have indicated that mu-
tated KRAS is associated with poor outcomes after therapy
with these agents.19,20
Unfortunately, there is often a lack of sufficient tumor
material available for biomarker analysis, including EGFR mu-
tation status, in patients with advanced stage NSCLC. However,
shed tumor DNA circulating in patient plasma may provide a
viable alternative for identification of tumor mutations and other
alterations.21 Patients with advanced cancer generally have
higher plasma concentrations of circulating DNA,22,23 which has
been shown to contain tumor-specific alterations.24,25 However,
conventional assays may lack the requisite sensitivity to fully
translate this concept into clinical utility.26
Newer methodologies such as Scorpion probes have
been used in combination with allele-specific amplification
(amplification refractory mutation system ARMS) in fluores-
cence-based real-time PCR offer the potential for increased
sensitivity in detecting circulating DNA mutations.27–29 Using
this technique, as a follow-up, we report detection of EGFR and
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KRAS mutations in plasma from patients with NSCLC re-
ceiving erlotinib-based therapy, with significant associations
observed between the presence of mutations and clinical
outcomes.30
MATERIALS AND METHODS
Blood Sample Collection and DNA Extraction
Whole blood specimens were collected immediately
before treatment, in ethylenediaminetetraacetic acid-tubes
and centrifuged at 1000 rpm for 15 minutes. DNA was
extracted from 0.5 to 2.0 mL of plasma using QIAamp DNA
Blood mini kit (Qiagen, Valencia, CA). Estimated final DNA
concentrations generally ranged from 1 to 9 ng/l, with an
average of 2.3 ng/l.
Tissue Specimens
All slides were H&E stained and underwent histologic
review for tumor content by a certified pathologist. Slides
were deparaffinized by xylene and dehydrated by 100%
ethanol. DNA was extracted using the QIAamp DNA mini kit
(Qiagen).
PCR and Direct Sequencing for EGFR
To detect mutations in EGFR exons 19, 20, and 21,
a nested PCR assay was used. External primer sequences
for each exon have been previously published.16 Addi-
tional primers and methodology are provided in Supple-
mentary Material (see Supplementary Digital Content 1,
http://links.lww.com/JTO/A11.
Scorpion-ARMS for EGFR and KRAS Mutations
EGFR and KRAS Scorpion test kits (DxS Ltd,
Manchester, UK), were used to detect mutations in DNA
using real-time PCR following the manufacturer’s proto-
col. Additional methodology and analyses are provided in
Supplementary Material (see Supplementary Digital Con-
tent 1, http://links.lww.com/JTO/A11).
Statistical Analysis
Survival distributions were summarized with Kaplan-
Meier plots and differences were assessed with the log-rank
test. A two-sided Fisher exact test was used to assess differ-
ences in patient response versus mutation status.
Patients and Clinical Trial Methodology
The phase I/II trial of docetaxel plus intercalated erlo-
tinib that forms the basis for this correlative science study
stemmed from preclinical data suggesting that pharmacody-
namic separation of these two agents resulted in superior
antitumor activity, as previously reported.30–33 The phase I
portion consisted of two arms conducted simultaneously with
docetaxel given every 21 days (70–75 mg/m2 intravenously)
to a maximum of six cycles. Arm B, where erlotinib was
administered on days 2 to 16 (150–300 mg), was chosen for
further study in a phase II expansion, enrolling patients with
previously treated stages IIIB and IV NSCLC. Forty-nine
patients with cytologically or histologically defined NSCLC
from either the phase I arms or the phase II study were
analyzed here. This study was approved by the respective
institutional review boards of participating institutions. All pa-
tients gave informed consent and the trial was conducted with
adherence to the Helsinki Declaration. Patient characteristics for
the entire cohort are summarized in Table 1.
RESULTS
In Vitro Evaluation of Scorpion-ARMS for
Detection of EGFR and KRAS Mutations
The sensitivity and specificity of Scorpions-ARMS was
tested using serial dilutions of EGFR-mutant, KRAS-mutant,
and wild-type (WT) NSCLC cell lines (Figure 1A, B). The
scorpions approach was able to detect each mutation at
percentages as low as 0.1% of total DNA content. In contrast,
detection by direct sequencing was negligible at 10% (Figure
1C). No false positive signals were observed for any probe in
this setting.
TABLE 1. Baseline Patient and Disease Characteristics of
Advanced Patients with Non-small Cell Lung Cancer Treated
with Docetaxel and Erlotinib
No. of Patients (N  48) %
Treatment arma
Phase I: arm A 7 14.6
Phase I: arm B 12 25.0
Phase II 29 60.4
Characteristic
Age, yr
Median 59
Range 34–79
Age 65 yr 31 64.6
Age 65 yr 17 35.4
Sex
Female 27 56.3
Male 21 43.7
Smoking status
Never-smoker 16 33.3
Former/current smoker 32 66.7
ECOG performance status
0 24 50.0
1 24 50.0
Race
African descent 2 4.2
White 44 91.6
East/South East Asian 2 4.2
Histological type
Adenocarcinoma 32 66.6
Squamous cell carcinoma 7 14.6
Other: NSCLC, NOS 9 18.8
a Phase I, Arm A: Docetaxel 70 mg day 1 and erlotinib 600–800 mg days 2, 9, and
16 on a 21-d cycle. Phase I, Arm B: Docetaxel 70–75 mg day 1 and erolotinib 150–300
mg days 2–16 on a 21-d cycle. Phase II: Docetaxel 70 mg day 1 and erlotinib 200 mg
days 2–16 on a 21-d cycle.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer;
NOS, not otherwise specified.
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EGFR Activating Mutations Are Predictive of
Response to Docetaxel Plus Erlotinib
The Scorpions-ARMS approach was used to detect
EGFR and KRAS mutations in plasma and tumor specimens
from patients with NSCLC enrolled on a phase I/II clinical
trial of docetaxel plus intermittent erlotinib. Archival paraffin
blocks or slides with analyzable material were available from
14 patients, whereas fresh frozen plasma specimens were
available from all 49 patients with NSCLC in this cohort. The
absence or presence of mutations was confirmed in an inde-
pendent run, and for analysis of plasma—from a separate
aliquot. A patient was considered positive if a mutation
was detected either in plasma or in tumor. Twelve EGFR
mutations were detected in 10 patients; whereas KRAS
mutations were detected in two patients (Table 2). Of the
10 patients that tested positive for EGFR mutations, six
were histologically classified as adenocarcinoma, one as
squamous cell carcinoma, and three as not otherwise spec-
ified. The KRAS and EGFR mutations were exclusive. Four
patients were positive for the exon 20 T790M mutation,
associated with resistance to erlotinib; two of which also
harbored additional EGFR activating mutations. Represen-
tative examples of EGFR and KRAS mutations are shown
in Figure 2.
Tumor mutational status was compared with patient
response to treatment (Figure 3). Both complete responders
harbored exon 19 deletions, readily detectable in both tumor
and plasma (Figure 2A). Of the patients with PR as best
response, four of 10 harbored activating mutations (two in
exon 19 and two in exon 21). All four patients with T790M
mutations had stable disease as best response. No activating
mutations were detected in any of the 13 patients with
progressive disease; however, in two of these patients, codon
12 KRAS mutations were observed. Patients with activating
mutations (absent the T790M resistant mutation) were sig-
nificantly more likely to respond to treatment (p  0.0002).
Table 2 shows individual characteristics for patients with
either an EGFR or a KRAS mutation.
FIGURE 1. Scorpion-amplification refractory mutation system (ARMS) assay sensitivity. Non-small cell lung cancer (NSCLC)
lines harboring epidermal growth factor receptor (EGFR) and KRAS mutations were serially diluted and analyzed by Scorpion-
ARMS. A, Genomic DNA was extracted from H1975 cells (mutations at L858R and T790M), H1650 (del746–750 mutation in
exon 19), and A549 cells (wild type WT EGFR). DNA from the EGFR-mutant cell lines was diluted with DNA from A549 at
the following ratios: 0, 0.5, 0.33, 0.1, 0.01, and 0.001. B, A dilution series for the KRAS codon 12 GGT3AGT using DNA from
A549 cells and H460 cells (WT at codon 12). C, Comparison between Scorpion-ARMS and DNA sequencing for the L858R
mutation.
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EGFR Activating Mutations Are Associated with
Improved PFS Following Treatment with
Docetaxel and Intermittent Erlotinib
The relationship between the EGFR/KRAS mutation
status and patient overall survival (OS) and progression-free
survival (PFS) times was investigated. For all 49 patients, the
median PFS was 5.4 months and the median OS was 18.8
months. Patients were stratified into subgroups based on the
following mutational genotypes: (1) positive for a single
EGFR activating mutation in exon 19 or 21 (E19del or
L858R), (2) WT EGFR, (3) presence of an exon 20 T790M
resistance mutation, and (4) positive for a KRAS codon 12 or
13 mutation. The PFS for each of these groups is graphed in
Figure 4A. Patients with activating mutations, absent a resis-
tance factor, had a favorable median PFS of 18.3 months (n
6). Patients harboring a T790M mutation had a median PFS
TABLE 2. Demographics and Tumor Histology of Patients Positive for EGFR or KRAS Mutations
Patient ID Mutation Response Smoking History Age Sex Histology Detected in
25 del746-750 CR Ex, 10 pack/yr 47 F Adeno P, T
76 del746-750 CR Ex, 2 packs/yr 61 F NOS P, T
11 L858R PR Never 44 M Adeno P
52 del746-750 PR Never 45 M Adeno T
57 L858R PR Never 67 F NOS P
66 del746-750 PR Current, 30 pack/yr 47 F Squam P, T
23 del and T790M SD Ex, 40 pack/yr 66 F Adeno T
8 L858R& T790M SD Unknown 54 F Adeno P
63 T790M SD Ex, 50 pack/yr 73 F Adeno P, T
19 T790M SD Ex 70 M NOS P
59 KRAS PD Never 38 M NOS P
28 KRAS PD Unknown 52 M Adeno P, T
For patients 11, 57, 8, 19, and 59, only plasma was available for analysis.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; P, plasma; T, tumor.
FIGURE 2. Representative examples of patient specimens positive for EGFR or KRAS mutations. A, Two patients with E19del
identified in both plasma and tumor DNA. Both patients had complete response to therapy. B, A patient specimen with de
novo positivity for both E19del and T790M. C, A patient with a KRAS mutation identified in both plasma and tumor.
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of 3.9 months (n 4), comparable with the 4.0 month PFS of
those with WT EGFR (n  37). Both patients with KRAS
mutations had poor outcomes, with a median PFS of less than
1.5 months. Patients with single EGFR activating mutations
(i.e., absent a resistance factor) had a significantly improved
PFS when compared with patients with WT EGFR (p 0.012),
or when compared with all other patients (p  0.0079).
Patients with EGFR activating mutations had a numer-
ically superior OS (median of 39.6 months); however, it was
not significantly superior to that of patients with WT EGFR
or T790M (17.8 and 24.2 months, respectively; Figure 4B).
The two patients harboring KRAS mutations performed
poorly, with a median OS of 2.5 months.
Predictive Utility of Plasma Analysis
Seven of the 12 patients who were positive for an
EGFR or KRAS mutation had tissue available for analysis
(Table 2). All cases that were positive for mutations in the
plasma were also positive in the tumor specimen. However,
two patients had mutations detectable in tumor tissue that
were not observed in plasma. When considered without the
tumor data, plasma-only analysis remained a significant pre-
dictor of patient outcome. Those with plasma-detected
mutations in exons 19 and 21 (absent a T790M resistance
mutation) had significantly improved PFS compared with
patients with WT EGFR (p  0.0122) or compared with WT
EGFR and T790M-postive patients combined (p  0.0088).
The association between response rate and activating muta-
tions detected in plasma also remained significant using the
dichotomization presented in Figure 3.
DISCUSSION
Here, we report the association of EGFR and KRAS
mutations in plasma using Scorpion-ARMS with patient out-
comes after erlotinib-based treatment. The presence of EGFR
activating mutations correlated significantly with improved
tumor response and PFS, but not OS, in patients treated with
docetaxel and intercalated erlotinib.30–33
FIGURE 3. Relationship between mutation-positivity and
patient response. Clinical response data, as determined us-
ing RECIST criteria, was available for 45 patients. Those posi-
tive for activating mutations (E19del or L858R) were signifi-
cantly associated with response to therapy (p  0.0002)
(labeled green). Four specimens were positive for T790M
mutations, two of which also contained activating mutations
(labeled yellow), occurring in patients with SD. Two KRAS
mutations were identified in patients with progressive dis-
ease (labeled red).
FIGURE 4. A, EGFR activating mutations correlate with en-
hanced progression-free survival (PFS). Kaplan-Meier plot
showing PFS of 49 patients stratified by mutation type. Pa-
tients with EGFR activating mutations (E19del or L858R) had
significantly improved PFS compared with patients with WT
EGFR or those harboring a resistance mutation (T790M or
KRAS). B, Overall survival by mutation type. Kaplan-Meier
plot showing overall survival of 49 patients stratified by mu-
tation type.
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In the studies described here, we directed our attention
toward detection of mutations of KRAS and the EGFR ty-
rosine kinase domain. Because tumor tissue was not available
for molecular analysis on most patients, we hypothesized that
utilization of the recently described Scorpions technology for
analysis of plasma DNA would aid in interpretation of the
clinical results. Six of 49 patients with NSCLC enrolled on
either the phase I or the phase II portion of this trial had
activating EGFR mutations in exons 19 or 21, all of whom
responded to treatment and as a group had significantly
extended PFS. Two of two complete responders harbored
exon 19 deletions that were readily detectable both in tissue
and in plasma. Unexpectedly, four patients were positive de
novo for T790M mutations in exon 20, previously associated
with resistance to EGFR TKIs. These patients all had stable
disease as best response and did not differ significantly in
survival from patients with WT EGFR. KRAS mutations were
detected in only two of the 49 patients; however, both of
these patients performed poorly, with a mean OS of only 2.5
months.
Seven of 12 patients who were positive for an EGFR or
KRASmutation had tissue available for analysis (Table 2). No
cases were plasma positive and tumor negative, consistent
with absence of false positivity for plasma detection in our
study. However, two patients had mutations detectable in
tumor tissue that were not observed in plasma, perhaps
related to low overall tumor volume. Overall, these data
suggest that analysis of shed tumor DNA in plasma can
supplement or even replace tumor tissue analysis, adding
significant predictive utility when archival specimens are not
available.
Our data, conducted in a U.S. population treated with
an erlotinib-based therapy and inclusive of KRAS and T790M
mutation analysis, expand on previous observations regarding
use of Scorpion-ARMS to detect EGFR mutations in plasma
DNA. Kimura et al.28 detected EGFRmutations in circulating
DNA from seven of 42 Japanese patients treated with ge-
fitinib. They noted significant correlations between mutation
positivity with patient response and with PFS. A study by
Kuang et al.34 evaluating 54 select patients from a U.S. cohort
previously treated with EGFR TKIs, found that 70% of
patients with EGFR mutations in their tumors also had
mutations in their shed DNA in plasma. Using a microfluid-
ics-based digital PCR design to detect EGFR mutations in 35
patients with NSCLC with paired plasma and tumor speci-
mens, Yung et al.35 found mutations in the plasma of 11 of 12
(92%) patients who were tumor-positive for EGFR muta-
tions. Maheswaran et al.36 recently reported on the use of
Scorpion-ARMS on circulating lung cancer cells for mutation
detection, identifying mutations in 11 of 12 patients known
previously to be mutation positive. Similar to our results,
these investigators identified a higher than expected number
of patients with pretreatment T790M mutations concurrent
with an activating mutation. However, none of our T790M-
positive patients had a dramatic response; whereas two of six
of theirs did, although the responses were not durable.
Unlike archival tissue specimens, collection of patient
plasma is easily standardized, limiting variability from han-
dling and is not subject to formalin-induced artifacts. In
addition, serial analysis over time can be performed to look
for treatment-related changes, such as resolution of a previ-
ously observed plasma EGFR mutation under the influence of
erlotinib. However, a limitation of plasma analysis is the
potential interpatient variability in the ratio of tumor to WT
circulating DNA.
In summary, we found that the presence of EGFR
activating mutations identified in circulating DNA in plasma,
correlated significantly with improved tumor response, and
PFS in patients treated with docetaxel plus intermittent erlo-
tinib. The use of docetaxel in this intercalated schedule did
not seem to diminish activity of erlotinib in patients harboring
EGFR mutations, nor alter the ability to detect favorable
patient outcomes associated with such activating mutations.
Indeed, a substantial number of patients with no evidence of
EGFR activating mutation showed clinical benefit from this
treatment paradigm. We conclude that, in the absence of
tumor tissue, detection of EGFR and KRAS mutations in
cell-free plasma DNA using Scorpion-ARMS is a viable
strategy with predictive utility.
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